-transparent.png){kind=logo}
Four subjects received 5 mg 14C-glipizide orally, 3 subjects 1 mg intravenously and 2 subjects 5 mg 14C-glibenclamide orally. Plasma levels of radioactivity, and urinary and faecal excretion were measured. For both drugs the disappearance of radioactivity from plasma followed complex kinetics and the apparent half-lives increased steadily with time. The two sulfonylureas were extensively metabolized and were excreted in the urine as hydroxylated or conjugated metabolites. The effects of both drugs on blood glucose and immunoreactive insulin were comparable. The findings are compared with other published results.
Related Publications
L Balant, and
J Fabre, and
G R Zahnd
January 1973,
The Journal of clinical pharmacology and new drugs,
L Balant, and
J Fabre, and
G R Zahnd
January 1985,
European journal of clinical pharmacology,
L Balant, and
J Fabre, and
G R Zahnd
February 1999,
Research communications in molecular pathology and pharmacology,
L Balant, and
J Fabre, and
G R Zahnd
February 1991,
Zhonghua nei ke za zhi,
L Balant, and
J Fabre, and
G R Zahnd
December 2000,
European journal of clinical pharmacology,
L Balant, and
J Fabre, and
G R Zahnd
November 2021,
Chemistry (Weinheim an der Bergstrasse, Germany),
L Balant, and
J Fabre, and
G R Zahnd
September 1973,
Diabetologia,
L Balant, and
J Fabre, and
G R Zahnd
September 1982,
International journal of clinical pharmacology, therapy, and toxicology,
L Balant, and
J Fabre, and
G R Zahnd
January 1995,
Yao xue xue bao = Acta pharmaceutica Sinica,
L Balant, and
J Fabre, and
G R Zahnd
November 1989,
International journal of clinical pharmacology, therapy, and toxicology,
